Nektar Therapeutics (NASDAQ: [[ticker:NKTR]]) has promoted Jonathan Zalevsky to chief research and development officer. Zalevsky joined the San Francisco drug developer in 2015 and has been its chief scientific officer since 2017. Nektar also announced that Gil Labrucherie has been promoted to chief operating officer in addition to his duties as chief financial officer. Nektar’s drug pipeline includes programs in cancer, autoimmune diseases, and chronic pain.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
